{"id":"NCT03275350","sponsor":"Oregon Health and Science University","briefTitle":"Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study (CHOICES) Scale-Up","officialTitle":"Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study (CHOICES) Scale-Up","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2018-02-05","primaryCompletion":"2019-11-08","completion":"2019-11-08","firstPosted":"2017-09-07","resultsPosted":"2022-04-27","lastUpdate":"2022-04-27"},"enrollment":114,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Opioid-use Disorder","Hiv"],"interventions":[{"type":"DRUG","name":"Naltrexone Injectable Suspension","otherNames":[]},{"type":"OTHER","name":"Treatment as usual","otherNames":[]}],"arms":[{"label":"XR-NTX","type":"ACTIVE_COMPARATOR"},{"label":"TAU","type":"ACTIVE_COMPARATOR"}],"summary":"The Primary Objective of this study is to compare the effectiveness of HIV clinic-based extended-release Naltrexone (XR-NTX) in decreasing substance use and increasing HIV viral suppression in HIV-infected participants with opioid use disorder to Treatment as Usual in this population.","primaryOutcome":{"measure":"Number of Participants With HIV Viral Suppression, Missing Imputed as Unsuppressed","timeFrame":"12 weeks and 24 weeks","effectByArm":[{"arm":"Extended-release Naltrexone (XR-NTX)","deltaMin":23,"sd":null},{"arm":"Treatment as Usual (TAU)","deltaMin":21,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":15},"locations":{"siteCount":5,"countries":["United States"]},"refs":{"pmids":["40342086","37712113","34758887"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":55},"commonTop":["Infections","Injury","Gastrointestinal disorders","Respiratory disorders","Psychiatric disorders"]}}